Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1376056 | Bioorganic & Medicinal Chemistry Letters | 2007 | 5 Pages |
Abstract
Development of a lead series of piperidinylurea CXCR3 antagonists has led to the identification of molecules with alternative linkages, which retain good potency. A piperidinyl thiadiazole derivative was found to have satisfactory in vitro metabolic stability and to be orally bioavailable in mice, giving high plasma concentrations and a half life of 5.4Â h.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Robert J. Watson, Daniel R. Allen, Helen L. Birch, Gayle A. Chapman, Duncan R. Hannah, Roland L. Knight, Johannes W.G. Meissner, David A. Owen, Elizabeth J. Thomas,